High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy

BACKGROUND: The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ther Adv Med Oncol
Hoofdauteurs: Yang, I-Ping, Miao, Zhi-Feng, Huang, Ching-Wen, Tsai, Hsiang-Lin, Yeh, Yung-Sung, Su, Wei-Chih, Chang, Tsung-Kun, Chang, Se-fen, Wang, Jaw-Yuan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2019
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6704420/
https://ncbi.nlm.nih.gov/pubmed/31467597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919866964
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items